Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  HIV Infection

  Free Subscription


Articles published in HIV Med

Retrieve available abstracts of 349 articles:
HTML format



Single Articles


    April 2026
  1. RACCAGNI AR, Lolatto R, Capra N, Loi G, et al
    Three settings, one goal: Performance of different HIV testing strategies at a tertiary centre in Milan.
    HIV Med. 2026 Apr 18. doi: 10.1111/hiv.70242.
    PubMed     Abstract available


  2. FOX D, Slim J, Overton ET, Doblado-Maldonado A, et al
    Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.
    HIV Med. 2026 Apr 16. doi: 10.1111/hiv.70237.
    PubMed     Abstract available


  3. HENDERSON M, Dutey-Magni P, Herrera C, Stohr W, et al
    Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART.
    HIV Med. 2026 Apr 16. doi: 10.1111/hiv.70236.
    PubMed     Abstract available


  4. HENALES IRUZUBIETA I, Romero Marin G, Patron Hernandez MA, Perez Stachowski J, et al
    Impact of the COVID-19 pandemic on missed opportunities for diagnosis of HIV infection: HUCS-ODIPER (missed diagnostic opportunities) study.
    HIV Med. 2026 Apr 14. doi: 10.1111/hiv.70243.
    PubMed     Abstract available


  5. MILIC J, Pugliese A, Belli M, Lonardi GL, et al
    A multidisciplinary, AI-supported quality improvement intervention to manage polypharmacy in aging people with HIV.
    HIV Med. 2026 Apr 11. doi: 10.1111/hiv.70234.
    PubMed     Abstract available


  6. RUSSO A, Giacomelli A, De Vito A, Mazzitelli M, et al
    Implementing the National Vaccination Plan in people with HIV in Italy: A survey among ICONA centres.
    HIV Med. 2026 Apr 11. doi: 10.1111/hiv.70241.
    PubMed    


  7. MARTIN Y, Surial B, Muller M, Baumann L, et al
    Do people with HIV really have the choice between oral and injectable ART? Evidence from a multicentric survey in the Swiss HIV cohort study.
    HIV Med. 2026 Apr 8. doi: 10.1111/hiv.70239.
    PubMed     Abstract available


  8. DA COSTA OLIVEIRA TN, Moreira RC, Carvalho LM, Coelho FC, et al
    Mortality trends for diabetes mellitus, hypertension and cardiovascular disease among people living with and without HIV in Brazil during the COVID-19 pandemic, 2020-2022.
    HIV Med. 2026 Apr 8. doi: 10.1111/hiv.70240.
    PubMed     Abstract available


  9. KIERI O, Jutte BB, Vesterbacka J, Aleman S, et al
    HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.
    HIV Med. 2026 Apr 5. doi: 10.1111/hiv.70235.
    PubMed     Abstract available


  10. LEON Z, Edun O, Zhou S, Tolmay J, et al
    Prevalence of low-level viremia and its association with virological failure among adolescents living with HIV in Eastern Cape, South Africa.
    HIV Med. 2026 Apr 5. doi: 10.1111/hiv.70228.
    PubMed     Abstract available


  11. CHEVALLIER TRB, Lampe FC, Johnson MA, Hunter A, et al
    Late HIV diagnosis and subsequent time to antiretroviral initiation and viral suppression in a large London HIV centre.
    HIV Med. 2026 Apr 3. doi: 10.1111/hiv.70232.
    PubMed     Abstract available


    March 2026
  12. CODONAL A, Lazaro A, Martinez E, Delgado A, et al
    Use of long-acting cabotegravir and rilpivirine in people living with HIV: A prospective observational cohort study.
    HIV Med. 2026 Mar 26. doi: 10.1111/hiv.70230.
    PubMed     Abstract available


  13. ARCOS-RUEDA MDM, De Miguel-Buckley R, De Gea Grela A, Busca C, et al
    Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy.
    HIV Med. 2026 Mar 25. doi: 10.1111/hiv.70231.
    PubMed     Abstract available


  14. KARAKOSTA A, Nicholls EJ, Coukan F, Nugent D, et al
    Missed opportunities to prevent HIV acquisition with pre-exposure prophylaxis: A mixed methods study of people with recently acquired HIV in the United Kingdom.
    HIV Med. 2026 Mar 19. doi: 10.1111/hiv.70222.
    PubMed     Abstract available


  15. NDLELA MG, Vilakati LN, Williams V, Ginindza NM, et al
    Cervical cancer screening adherence following initial HIV testing in Eswatini.
    HIV Med. 2026 Mar 19. doi: 10.1111/hiv.70227.
    PubMed     Abstract available


  16. JOSEPH PE, Itaeli AM, Amour M, Bwire GM, et al
    Effects of transition from paediatric to adult HIV care on virological outcomes in sub-Saharan Africa: A systematic review and meta-analysis.
    HIV Med. 2026 Mar 13. doi: 10.1111/hiv.70221.
    PubMed     Abstract available


  17. ZHANG X, Li C, Zhang Y, Jin Y, et al
    Global, regional, and national burden of HIV among children aged 0-14 years: Estimates and socioeconomic inequalities, 1990-2021.
    HIV Med. 2026 Mar 13. doi: 10.1111/hiv.70223.
    PubMed     Abstract available


  18. FALK S, Nilsson J, Moller IK, Elvstam O, et al
    Late diagnosis of HIV persists in Sweden: Differing social determinants among migrant and non-migrant people with HIV.
    HIV Med. 2026 Mar 12. doi: 10.1111/hiv.70217.
    PubMed     Abstract available


  19. AL-KAABI M, Castley A, Deshpande P, Chopra A, et al
    The impact of accumulating immune adaptation in circulating strains of HIV-1.
    HIV Med. 2026 Mar 8. doi: 10.1111/hiv.70215.
    PubMed     Abstract available


  20. LELEUX O, Peyrouny-Mazeau A, Perrier A, Hessamfar M, et al
    Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort.
    HIV Med. 2026 Mar 7. doi: 10.1111/hiv.70220.
    PubMed     Abstract available


  21. SALVO PF, Lombardi F, Torti C, Di Giambenedetto S, et al
    Clinical management of detectable viraemia during CAB/RPV long-acting therapy: Are really PIs the only exit strategies?
    HIV Med. 2026 Mar 6. doi: 10.1111/hiv.70219.
    PubMed    


  22. RASTEGAR S, Gaisa MM, Xu X, Winters J, et al
    Perianal lesions in men who have sex with men living with HIV: Risk of precancer and cancer.
    HIV Med. 2026 Mar 6. doi: 10.1111/hiv.70218.
    PubMed     Abstract available


  23. FLAVELL CA, Crowe M, Kenchington P, Jones A, et al
    Disability and frailty in people living with Human Immunodeficiency Virus in regional Australia: A cross-sectional study with a measurement property assessment of the HIV Disability Questionnaire.
    HIV Med. 2026 Mar 5. doi: 10.1111/hiv.70212.
    PubMed     Abstract available


  24. WEIS N, Chirwa M, Sabin CA
    Recognizing international Women's day 2026.
    HIV Med. 2026 Mar 3. doi: 10.1111/hiv.70213.
    PubMed    


  25. ZHANG L, Chen L, Tang J, Liu X, et al
    Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system.
    HIV Med. 2026 Mar 3. doi: 10.1111/hiv.70205.
    PubMed     Abstract available


    February 2026
  26. PURUSOTHMAN P, Barbisoni L, Leoni D, Sasset L, et al
    The outcomes of anxiety and depression symptom screening in a population with HIV: Insights from an HIV service in Northern Italy.
    HIV Med. 2026 Feb 27. doi: 10.1111/hiv.70211.
    PubMed     Abstract available


  27. BENEDITTIS S, Tavelli A, Gagliardini R, Bini T, et al
    Peer-supported digital collection of patient-reported outcomes in HIV care: Promise, practical barriers and lessons from a pilot study within the ICONA cohort.
    HIV Med. 2026 Feb 25. doi: 10.1111/hiv.70214.
    PubMed     Abstract available


  28. CARUSO E, Tavelli A, De Bona A, Frattini N, et al
    Achieving reimbursable PrEP is insufficient to increase and diversify the users attending community-based services.
    HIV Med. 2026 Feb 22. doi: 10.1111/hiv.70209.
    PubMed     Abstract available


  29. BRUNO S, Olivier R, Valerie P, Paul L, et al
    Treatment durability, satisfaction and quality of life in virologically suppressed HIV-1 people switching to doravirine: Results from the French study DoraVIH.
    HIV Med. 2026 Feb 19. doi: 10.1111/hiv.70210.
    PubMed     Abstract available


  30. HESKIN J, Movahedi R, Kang S, Byrne R, et al
    The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteers.
    HIV Med. 2026 Feb 18. doi: 10.1111/hiv.70208.
    PubMed     Abstract available


  31. BARBER TJ, Akinosoglou K, Bernardino JI, Koppe U, et al
    Highlights from the 20th European AIDS Conference: 15-18 October 2025, Paris, France.
    HIV Med. 2026 Feb 12. doi: 10.1111/hiv.70195.
    PubMed     Abstract available


  32. MOUSSE A, Allavena C, Gagneux-Brunon A, Raffi F, et al
    Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort.
    HIV Med. 2026 Feb 11. doi: 10.1111/hiv.70207.
    PubMed     Abstract available


  33. BALLENY R, Wong JMH, Lee T, Bitnun A, et al
    Perinatal and early infant outcomes after first-versus second-generation integrase strand transfer inhibitor use in pregnancy.
    HIV Med. 2026 Feb 10. doi: 10.1111/hiv.70206.
    PubMed     Abstract available


  34. KOKORELIAS KM, Sheppard CL, Eaton A, Wasilewski MB, et al
    Understanding the implementation of patient navigation for adults living with HIV: A scoping review of components, equity considerations and lessons learned.
    HIV Med. 2026 Feb 9. doi: 10.1111/hiv.70194.
    PubMed     Abstract available


  35. SILVESTRE C, Gross A, Makinson A
    Immune non-response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches.
    HIV Med. 2026 Feb 4. doi: 10.1111/hiv.70197.
    PubMed     Abstract available


  36. SIRIBELLI A, Capra N, Lolatto R, Bertoni C, et al
    Hypertriglyceridaemia and gender differences in the risk of major adverse cardiovascular events in people with HIV: A single-centre retrospective longitudinal study.
    HIV Med. 2026 Feb 2. doi: 10.1111/hiv.70203.
    PubMed     Abstract available


  37. SHERIDAN R, Osei-Kuffour Ekert Y, Campbell L, Zuckerman M, et al
    Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy.
    HIV Med. 2026 Feb 1. doi: 10.1111/hiv.70204.
    PubMed     Abstract available


    January 2026
  38. ELKHEIR N, Singh S, Barbini B, Campbell L, et al
    Screening for Trypanosoma cruzi infection (Chagas disease) in the Latin American population living with HIV in London.
    HIV Med. 2026 Jan 29. doi: 10.1111/hiv.70201.
    PubMed     Abstract available


  39. DE VITO A, Marongiu A, Cano A, Puci M, et al
    Exploring the impact of Cabotegravir-Rilpivirine long-acting on weight gain, body composition and quality of life in adults living with HIV.
    HIV Med. 2026 Jan 28. doi: 10.1111/hiv.70202.
    PubMed     Abstract available


  40. LIMA LV, Pavinati G, Beraldi-Magalhaes F, Andrade-Goncalves RLP, et al
    Hierarchical analysis of unsuccessful tuberculosis treatment among people living with HIV in Brazil using nationwide surveillance data.
    HIV Med. 2026 Jan 28. doi: 10.1111/hiv.70200.
    PubMed     Abstract available


  41. CAO T, Chen X, Chen H, Lu X, et al
    Preferences for long-acting antiretroviral therapy among people with HIV: A systematic review of discrete choice experiments.
    HIV Med. 2026 Jan 25. doi: 10.1111/hiv.70198.
    PubMed     Abstract available


  42. TROYA J, Mican R, Galindo MJ, Bisbal O, et al
    Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.
    HIV Med. 2026 Jan 25. doi: 10.1111/hiv.70196.
    PubMed     Abstract available


  43. ASENSI V, Cabo R, Garcia R, Fernandez L, et al
    Y181C-associated virologic failure during long-acting injectable cabotegravir/Rilpivirine in a patient engaged in intensive intravenous Chemsex.
    HIV Med. 2026 Jan 23. doi: 10.1111/hiv.70199.
    PubMed     Abstract available


  44. SHRAIDA T, Kwak E, Patterson R, Enkhbat U, et al
    Sex and gender differences in weight gain associated with second-generation integrase strand transfer inhibitors: A scoping review.
    HIV Med. 2026 Jan 20. doi: 10.1111/hiv.70190.
    PubMed     Abstract available


  45. WILDE P, de Queiros VS, Jaggers JR, Sabag A, et al
    Psychological responses to interval and continuous exercise in people living with HIV: A single-blind, counterbalanced, crossover study.
    HIV Med. 2026 Jan 19. doi: 10.1111/hiv.70193.
    PubMed     Abstract available


  46. MUSSINI C, Henegar C, Assoumou L, de Wit S, et al
    Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study.
    HIV Med. 2026 Jan 7. doi: 10.1111/hiv.70187.
    PubMed     Abstract available


  47. FONCHAM J, Azarmju F, Shen T, Salters K, et al
    Individual characteristics and time-updated factors associated with antiretroviral treatment interruptions among people living with HIV in British Columbia, Canada.
    HIV Med. 2026 Jan 6. doi: 10.1111/hiv.70188.
    PubMed     Abstract available


  48. YAN L, Xiao Q, Tuo L, Liu Y, et al
    Long-term immune reconstitution patterns and influencing factors in people living with HIV exhibiting suboptimal immune response after 24 months of antiretroviral therapy.
    HIV Med. 2026 Jan 5. doi: 10.1111/hiv.70192.
    PubMed     Abstract available


  49. AKBULUT I, Varol ZS, Singil S, Filiz MN, et al
    Quality of life and associated factors among people living with HIV in Turkiye: A single-centre experience.
    HIV Med. 2026 Jan 4. doi: 10.1111/hiv.70191.
    PubMed     Abstract available


    December 2025
  50. HYDE R, van Schaik P, Lawrence C, Forbes G, et al
    HIV testing in primary care in a low-prevalence area of Northeast England.
    HIV Med. 2025 Dec 31. doi: 10.1111/hiv.70189.
    PubMed     Abstract available


  51. SUAREZ-GARCIA I, Alejos B, Moreno C, de Miguel R, et al
    Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort.
    HIV Med. 2025 Dec 31. doi: 10.1111/hiv.70183.
    PubMed     Abstract available


  52. DHAIRYAWAN R, Paparini S, Smuk M, Sidat S, et al
    Supporting long-term engagement in HIV clinical care: Learning from the COVID-19 pandemic.
    HIV Med. 2025 Dec 31. doi: 10.1111/hiv.70181.
    PubMed     Abstract available


  53. SEZER B, Aydogdu T, Ata B
    Knowledge and attitudes toward HIV/AIDS among Turkish clinical medical and dental students.
    HIV Med. 2025 Dec 30. doi: 10.1111/hiv.70146.
    PubMed     Abstract available


  54. BAUCHER E, Gilles C, Manigart Y, Barlow P, et al
    Risk factors, management, and HPV genotyping of vulvar intraepithelial neoplasia (VIN) in women living with HIV: A comparison with women without HIV and a case control study.
    HIV Med. 2025 Dec 30. doi: 10.1111/hiv.70184.
    PubMed     Abstract available


  55. KOKORELIAS KM, Rochon P, Zhabokritsky A, Walmsley SL, et al
    Midlife and beyond: Integrating menopause and cervical screening for women and gender-diverse people living with HIV.
    HIV Med. 2025 Dec 25. doi: 10.1111/hiv.70186.
    PubMed    


  56. MAZZITELLI M, Boffito M, Torti C
    Review on: Polypharmacy in HIV: Rethinking what counts and why it matters.
    HIV Med. 2025 Dec 25. doi: 10.1111/hiv.70185.
    PubMed    


  57. PORCHIA DD, Wang Y, Zhou Z, Chen M, et al
    Cannabis use, microbial diversity and Dialister abundance in older adults with HIV: A cross-sectional study.
    HIV Med. 2025 Dec 22. doi: 10.1111/hiv.70180.
    PubMed     Abstract available


  58. GOZLAN Y, Wertheim JO, Mor O, Elbirt D, et al
    Deciphering HIV-1 transmission in young adults: Phylogenetic analysis reveals varied histories and an elite controller.
    HIV Med. 2025 Dec 22. doi: 10.1111/hiv.70182.
    PubMed     Abstract available


  59. MAZZITELLI M, Purusothman P, Calandrino L, Suchak T, et al
    HIV diagnosis and treatment outcomes in cis- and trans-gender women across two European centres: A comparative observational study.
    HIV Med. 2025 Dec 21. doi: 10.1111/hiv.70160.
    PubMed     Abstract available


  60. HIRANBURANA N, Sophonphan J, Kerr SJ, Lertpiriyasuwat C, et al
    Efficacy and predictors of virological non-suppression in Thailand's rollout of dolutegravir-based first-line antiretroviral therapy: A nationwide cohort analysis.
    HIV Med. 2025 Dec 19. doi: 10.1111/hiv.70178.
    PubMed     Abstract available


  61. JASPERSE J, Harris RJ, Humphreys C, Martin V, et al
    Risk factors for late HIV diagnosis in England, 2015-2023.
    HIV Med. 2025 Dec 18. doi: 10.1111/hiv.70156.
    PubMed     Abstract available


  62. CURTO C, Tritzali M, Bamford A, Bailey AC, et al
    Late diagnosis of paediatric HIV infection in high-income countries: Lessons from the HIV Perinatal Virtual Clinic.
    HIV Med. 2025 Dec 12. doi: 10.1111/hiv.70164.
    PubMed     Abstract available


  63. GARTLAND M, Wang X, Liao Q, Li B, et al
    Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study.
    HIV Med. 2025 Dec 12. doi: 10.1111/hiv.70154.
    PubMed     Abstract available


  64. NOORMAN MAJ, de Wit JBF, Marcos TA, Stutterheim SE, et al
    Towards inclusive HIV cure development: Identifying important and acceptable HIV cure attributes and strategies among people with HIV in the Netherlands.
    HIV Med. 2025 Dec 10. doi: 10.1111/hiv.70165.
    PubMed     Abstract available


  65. COSMARO ML, Penon S, Falzetta F, Candela C, et al
    TelePrEP in Italy: A remote service to expand equitable access to HIV pre-exposure prophylaxis.
    HIV Med. 2025 Dec 8. doi: 10.1111/hiv.70179.
    PubMed     Abstract available


  66. VAN BECKHOVEN D, Serrien B, Demeester R, Van Praet J, et al
    Reply to Satapathy et al.'s comment on "Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022".
    HIV Med. 2025 Dec 7. doi: 10.1111/hiv.70163.
    PubMed    


  67. SATAPATHY P, Mehta R, Sah R
    Comment on "Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022".
    HIV Med. 2025 Dec 7. doi: 10.1111/hiv.70116.
    PubMed    


  68. LE NT, Ta ND, Vu TT, Tran KX, et al
    Assessing cancer-related mortality risk among people with HIV in Vietnam: A nationwide population study.
    HIV Med. 2025 Dec 6. doi: 10.1111/hiv.70161.
    PubMed     Abstract available


  69. STEPHAN C, Albuquerque B, Schreiber S
    Authors' Reply to Letter to the Editor Regarding 'Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNE
    HIV Med. 2025 Dec 1. doi: 10.1111/hiv.70159.
    PubMed    


  70. RACCAGNI AR, Passini F, Lolatto R, Capra N, et al
    User-reported outcomes of long-acting injectable PrEP with Cabotegravir: Real-world experience from Milan.
    HIV Med. 2025 Dec 1. doi: 10.1111/hiv.70162.
    PubMed     Abstract available


  71. SURIAL B, Alagaratnam J
    HIV and cancer: Bridging two fields in transformation.
    HIV Med. 2025;26:1906-1908.
    PubMed    


    November 2025
  72. COUKAN F, Ogaz D, Saunders J, Murphy G, et al
    HIV PrEP use and unmet need among gay, bisexual and other men who have sex with men in London: An analysis of community cross-sectional surveys in England 2019-2022.
    HIV Med. 2025 Nov 30. doi: 10.1111/hiv.70157.
    PubMed     Abstract available


  73. ZHANG H, Xia H, Shi F, Li Q, et al
    Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program.
    HIV Med. 2025 Nov 30. doi: 10.1111/hiv.70155.
    PubMed     Abstract available


  74. ZHU JC, Hu WP, Zhang J
    Identification of GSR and CBR1 as biomarkers in HIV-associated emphysema through transcriptomic analysis.
    HIV Med. 2025 Nov 28. doi: 10.1111/hiv.70153.
    PubMed     Abstract available


  75. PROTOPAPAS K, Moschopoulos CD, Kalesis N, Mameletzis I, et al
    Informal PrEP use in Greece: The long, hard road to formal programmatic implementation.
    HIV Med. 2025 Nov 28. doi: 10.1111/hiv.70158.
    PubMed     Abstract available


  76. TEH HS, Tay KH, Lim YMF, Yang SL, et al
    Cardiovascular disease in people living with HIV in Malaysia: A competing risks cohort analysis.
    HIV Med. 2025 Nov 24. doi: 10.1111/hiv.70145.
    PubMed     Abstract available


  77. ST CLAIR-SULLIVAN N, Bristowe K, Bremner S, Maddocks M, et al
    Comprehensive geriatric assessment for people living with HIV and frailty: A mixed-methods feasibility randomized controlled trial.
    HIV Med. 2025 Nov 21. doi: 10.1111/hiv.70149.
    PubMed     Abstract available


  78. ADEDOKUN KA, Adebisi TA, Bello A, Fayemo HT, et al
    HIV/AIDS in transition: Global disparities, Africa's uneven progress and struggles, and the emerging threat of funding cuts (global burden of disease study, 1990-2021).
    HIV Med. 2025 Nov 21. doi: 10.1111/hiv.70144.
    PubMed     Abstract available


  79. SUAREZ-GARCIA I, Alejos B, Moreno C, Izquierdo R, et al
    Diagnosis of HIV infection during pregnancy: Trends from a national cohort in Spain.
    HIV Med. 2025 Nov 21. doi: 10.1111/hiv.70148.
    PubMed     Abstract available


  80. SEBOK-SYER SS, Tapper AR, Pasao MA, Nawy RN, et al
    Barriers and mitigating strategies to routine HIV screening in emergency departments: A national qualitative study.
    HIV Med. 2025 Nov 21. doi: 10.1111/hiv.70150.
    PubMed     Abstract available


  81. HERNANDEZ-PEREIRA M, Du J, Soldado-Folgado J, Carbonell I, et al
    Cross-sectional comparison of cardiovascular risk scores in people with HIV.
    HIV Med. 2025 Nov 21. doi: 10.1111/hiv.70152.
    PubMed     Abstract available


  82. MOTLOKWA PK, Ruffieux Y, Chinogurei C, Haas AD, et al
    Survival among medically insured and treated head and neck cancer patients with and without HIV in South Africa.
    HIV Med. 2025 Nov 19. doi: 10.1111/hiv.70143.
    PubMed     Abstract available


  83. DYER CEF, Jin F, Roberts JM, Poynten IM, et al
    Anal cancer screening in men who have sex with men living with HIV: The pilot of anal screening study (PASS).
    HIV Med. 2025 Nov 18. doi: 10.1111/hiv.70151.
    PubMed     Abstract available


  84. KNOX C, Wright J, Levett T
    A cross-sectional comparison of the use of frailty assessment tools in older people living with HIV.
    HIV Med. 2025 Nov 13. doi: 10.1111/hiv.70125.
    PubMed     Abstract available


  85. MA Y, Lohman M, Brown MJ, Li Y, et al
    Temporal network analysis of comorbidities among people with HIV in South Carolina.
    HIV Med. 2025 Nov 12. doi: 10.1111/hiv.70147.
    PubMed     Abstract available


  86. WALDECKER M, Taghavi K, Pasin C, Tarr PE, et al
    Factors associated with uptake of gynaecological care and cervical cancer screening among women in the Swiss HIV Cohort Study.
    HIV Med. 2025 Nov 11. doi: 10.1111/hiv.70137.
    PubMed     Abstract available


  87. WHITLOCK G, Gedela K
    Who's missing from London's HIV prevention response?
    HIV Med. 2025 Nov 7. doi: 10.1111/hiv.70141.
    PubMed    


  88. ANDOH J, Taghavi K, Moono M, Basu P, et al
    Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia.
    HIV Med. 2025 Nov 5. doi: 10.1111/hiv.70134.
    PubMed     Abstract available


  89. CHRISTENSEN AJ, Omann LR, Carlsson J, Baluku JB, et al
    Prevalence of current substance and hazardous alcohol use among people with HIV and tuberculosis disease and its impact on tuberculosis treatment outcomes: A systematic review.
    HIV Med. 2025 Nov 5. doi: 10.1111/hiv.70139.
    PubMed     Abstract available


  90. MISPELBAUM R, Hattenhauer T, Hoffmann C, Lehmann C, et al
    Effective and safe use of immune checkpoint inhibitors for non-small cell lung cancer in people living with HIV.
    HIV Med. 2025 Nov 5. doi: 10.1111/hiv.70136.
    PubMed     Abstract available


  91. BONI S, Debaudrap P, Kabore FN, Kasile-Pooda E, et al
    Long-term risk and predictors of high-risk human papillomavirus persistence after thermal ablation amongst women living with HIV in West Africa.
    HIV Med. 2025 Nov 3. doi: 10.1111/hiv.70138.
    PubMed     Abstract available


  92. DARLING KEA, Damas J, Frei AL, Frega S, et al
    Quality improvement report: Investigating barriers in HIV testing oncology patients to optimize HIV testing practice.
    HIV Med. 2025 Nov 2. doi: 10.1111/hiv.70140.
    PubMed     Abstract available


  93. BYRNE L
    BHIVA guidelines on the management of HIV in pregnancy and the postpartum period 2025.
    HIV Med. 2025;26:1757-1880.
    PubMed    


  94. CALDERON M, Alarcon Y, Alave J, Lopez O, et al
    Bridging borders in HIV care education: Lessons from an online multidisciplinary international exchange programme.
    HIV Med. 2025;26:1887-1893.
    PubMed     Abstract available


  95. COVA A, Ritchie CS, Godfrey M, Ghoshhajra B, et al
    Inflammatory profiles in older people with and without HIV in rural Uganda.
    HIV Med. 2025;26:1894-1901.
    PubMed     Abstract available


    October 2025
  96. POYNTEN IM, Turner RC, Varma R, Costello J, et al
    Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.
    HIV Med. 2025 Oct 23. doi: 10.1111/hiv.70133.
    PubMed     Abstract available


  97. SUKUMARAN L, Winston A, Marzolini C, Khoo S, et al
    Polypharmacy in HIV: Rethinking what counts and why it matters.
    HIV Med. 2025 Oct 21. doi: 10.1111/hiv.70129.
    PubMed     Abstract available


  98. TROYA J, Montes ML, Galindo MJ, Santiago AD, et al
    Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.
    HIV Med. 2025 Oct 21. doi: 10.1111/hiv.70114.
    PubMed     Abstract available


  99. DAYALAN N, Leung S, Dahill K, Temple A, et al
    Integrase inhibitors and paclitaxel for Kaposi sarcoma: Clinical relevance of pharmacological interaction.
    HIV Med. 2025 Oct 19. doi: 10.1111/hiv.70130.
    PubMed    


  100. ZHAO Y, Fu X, Yang Y, Shi L, et al
    Comorbidities, comedications and potential drug-drug interactions among people living with HIV in China.
    HIV Med. 2025 Oct 16. doi: 10.1111/hiv.70127.
    PubMed     Abstract available


  101. ARCOS-RUEDA MDM, Gil Garrote S, Torres Garcia EG, de Gea Grela A, et al
    Trends in acute hepatitis B among people living with HIV over 25 years: Incidence and clinical outcomes.
    HIV Med. 2025 Oct 15. doi: 10.1111/hiv.70132.
    PubMed     Abstract available


  102. O'REILLY M, Wohl DA, Hall S, Canijta EJP, et al
    A community and clinical collaboration to optimize HIV treatment and care for people with HIV in Australia-Solutions from the Beyond Undetectable symposium.
    HIV Med. 2025 Oct 15. doi: 10.1111/hiv.70110.
    PubMed     Abstract available


  103. AMBROSIONI J, Levi LI, Alagaratnam J, Sempere A, et al
    Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025.
    HIV Med. 2025 Oct 15. doi: 10.1111/hiv.70120.
    PubMed     Abstract available


  104. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo-Uixeda S
    Letter to the editor on "Effectiveness, safety and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study".
    HIV Med. 2025 Oct 13. doi: 10.1111/hiv.70071.
    PubMed    


  105. MCQUILLAN O, Carnes L, Croston M, Delaney J, et al
    HIV-related stigma mandatory training in healthcare-carrot versus stick.
    HIV Med. 2025 Oct 13. doi: 10.1111/hiv.70124.
    PubMed    


  106. SYAMSIR SB, Setiawan A, Natashia D, Purwati NH, et al
    "I cry alone because I'm so exhausted": Family caregivers' perspectives on mHealth support in paediatric HIV care in Indonesia.
    HIV Med. 2025 Oct 12. doi: 10.1111/hiv.70126.
    PubMed     Abstract available


  107. FAGGIANO T, Yin J, Patel N, Karim A, et al
    Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy.
    HIV Med. 2025 Oct 12. doi: 10.1111/hiv.70128.
    PubMed     Abstract available


  108. SCHUETTFORT G, Borch J, Cabello A, Crusells M, et al
    Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.
    HIV Med. 2025 Oct 7. doi: 10.1111/hiv.70119.
    PubMed     Abstract available


  109. BARRE T, Ramier C, Protopopescu C, Sogni P, et al
    Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi-center survey in France (ANRS CO13 HEPAVIH).
    HIV Med. 2025 Oct 1. doi: 10.1111/hiv.70121.
    PubMed     Abstract available


  110. CHAN P, Moreland S, Sacdalan C, Colby DJ, et al
    Blood pressure and metabolic outcomes after efavirenz- or dolutegravir-based therapy started in acute HIV infection.
    HIV Med. 2025;26:1619-1625.
    PubMed     Abstract available


  111. WHITLOCK G, Cole S, Khurshid A, Boffito M, et al
    HIV prevention in London, UK, from 2017 to 2024: Outcomes, gaps and learnings.
    HIV Med. 2025;26:1612-1618.
    PubMed     Abstract available



  112. Abstracts of the 20th European AIDS Conference 2025, October 15-18, 2025, Paris, France.
    HIV Med. 2025;26 Suppl 4:5-701.
    PubMed    



  113. Abstracts of the 20th European AIDS Conference 2025, October 15-18, 2025, Paris, France.
    HIV Med. 2025;26 Suppl 4:702-763.
    PubMed    


    September 2025
  114. GAROFOLI N, Flandre P, Vincensini JP, Richier Q, et al
    Impact on weight of a Doravirine switch in people living with HIV.
    HIV Med. 2025 Sep 30. doi: 10.1111/hiv.70123.
    PubMed     Abstract available


  115. TWABI HH, Ueno A, Ives J, Murtagh R, et al
    Diagnostic accuracy of the WHO clinical staging system for detection of immunologically defined advanced HIV disease: A systematic review and meta-analysis.
    HIV Med. 2025 Sep 26. doi: 10.1111/hiv.70122.
    PubMed     Abstract available


  116. SAVINELLI S, Heeney A, Tinago W, Garcia Leon AA, et al
    People living with HIV on modern antiretrovirals do not display a pro-atherogenic lipid profile and have similar body composition compared to healthy controls.
    HIV Med. 2025 Sep 24. doi: 10.1111/hiv.70118.
    PubMed     Abstract available


  117. AVALLONE F, Engler K, Hickson F, Cox J, et al
    Sexual dysfunction care needs of gay, bisexual, and other men who have sex with men living with HIV in Montreal, Canada.
    HIV Med. 2025 Sep 22. doi: 10.1111/hiv.70115.
    PubMed     Abstract available


  118. FARINA F, Datta A, Morin SN, Saeed S, et al
    Intersections of vitamin D deficiency, HIV and chronic liver diseases.
    HIV Med. 2025 Sep 20. doi: 10.1111/hiv.70117.
    PubMed     Abstract available


  119. LO HOG TIAN JM, Watson JR, Tran A, Maunder RG, et al
    The moderating effect of healthcare empowerment on the relationship between stigma and self-rated health in people living with HIV in Canada.
    HIV Med. 2025 Sep 15. doi: 10.1111/hiv.70108.
    PubMed     Abstract available


  120. ELIAS A, Pasin C, Smuk M, Paterson A, et al
    Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations.
    HIV Med. 2025 Sep 13. doi: 10.1111/hiv.70113.
    PubMed     Abstract available


  121. SHORT WR, Willame C, Nguyen H, Zhang B, et al
    Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States: Findings from the antiretroviral pregnancy registry.
    HIV Med. 2025 Sep 11. doi: 10.1111/hiv.70112.
    PubMed     Abstract available


  122. SHAIK F, Uldrick TS, Mazinu M, Gwebushe N, et al
    Cytokine biomarkers and their relationship to symptoms and quality of life in people with HIV-associated Kaposi sarcoma.
    HIV Med. 2025 Sep 10. doi: 10.1111/hiv.70107.
    PubMed     Abstract available


  123. OZDEMIR A, Demir T, Polat C, Uzun M, et al
    Molecular epidemiological analysis and investigation of antiretroviral drug resistance profile, including capsid inhibitors, among treatment-naive individuals with HIV-1 in Turkiye.
    HIV Med. 2025 Sep 7. doi: 10.1111/hiv.70109.
    PubMed     Abstract available


  124. HASEBE S, Kusaka T, Tanaka M, Iwane S, et al
    Dual drivers of polypharmacy in people with HIV: Quantifying the independent associations of aging and long-term antiretroviral therapy.
    HIV Med. 2025 Sep 5. doi: 10.1111/hiv.70106.
    PubMed     Abstract available


  125. DZANDO G, Ward PR, Mwanri L, Agbadi P, et al
    Multidimensional frailty, sex differences, and quality of life among older Ugandans affected by HIV.
    HIV Med. 2025 Sep 5. doi: 10.1111/hiv.70111.
    PubMed     Abstract available


  126. STOYANOVA A, Foster F, Savin P, Amanzholov N, et al
    Examination of factors associated with mental health of people living with HIV in Kazakhstan: A cross-sectional study based on the two-continua model.
    HIV Med. 2025 Sep 5. doi: 10.1111/hiv.70100.
    PubMed     Abstract available


  127. ORLOVA-MOROZOVA E, Kireev D, Kirichenko A, Bobkov V, et al
    Real-world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV-1 sub-subtype A6 harbouring the L74I mutation.
    HIV Med. 2025;26:1463-1467.
    PubMed     Abstract available


    August 2025
  128. PIERONE G JR, Brunet L, Fusco JS, Sension MG, et al
    Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort.
    HIV Med. 2025 Aug 30. doi: 10.1111/hiv.70105.
    PubMed     Abstract available


  129. KEANE A, Haberl L, Aho I, Bernardi S, et al
    European Guidelines on HIV and breastfeeding: "Same, same, but different" - Results from a WAVE survey.
    HIV Med. 2025 Aug 25. doi: 10.1111/hiv.70072.
    PubMed     Abstract available


  130. CACHO J, Nomah DK, Egri N, Cofan F, et al
    Cellular and humoral response after mRNA SARS-CoV-2 vaccination in kidney transplant recipients living with HIV: A cross-sectional study.
    HIV Med. 2025 Aug 25. doi: 10.1111/hiv.70087.
    PubMed     Abstract available


  131. WENDT GW, Chaves LW, Costa AB
    Exploring the influence of age, gender, stigma, and years living with HIV on mental health outcomes.
    HIV Med. 2025 Aug 19. doi: 10.1111/hiv.70098.
    PubMed     Abstract available


  132. GRIFFIN DWJ, McMahon JH, Ruschena DA, Hoy JF, et al
    Solid organ transplantation in people with HIV: Outcomes, obstacles and opportunities.
    HIV Med. 2025 Aug 15. doi: 10.1111/hiv.70099.
    PubMed     Abstract available


  133. CLIFTON B, Keen P, Trevillyan J, Sullivan N, et al
    Strategies to achieve the UNAIDS 95% HIV diagnosis target in Australia: Insights from a multidisciplinary roundtable.
    HIV Med. 2025 Aug 15. doi: 10.1111/hiv.70083.
    PubMed     Abstract available


  134. ADACHI E, Minami R, Shirano M, Nakamura H, et al
    Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.
    HIV Med. 2025 Aug 9. doi: 10.1111/hiv.70096.
    PubMed     Abstract available


  135. BEHRENS GMN, Assoumou L, De Wit S, MacDonald R, et al
    Morbidity and risk factors of COVID-19 in people with HIV-1 in Europe: A combined observational cohort and nested case-control study.
    HIV Med. 2025 Aug 7. doi: 10.1111/hiv.70094.
    PubMed     Abstract available


  136. WEIBULL WARNBERG A, Cena-Diez R, Sonnerborg A, van de Klundert MAA, et al
    Natural occurrence of drug resistance mutations to the HIV-1 capsid inhibitor lenacapavir.
    HIV Med. 2025 Aug 7. doi: 10.1111/hiv.70092.
    PubMed     Abstract available


  137. NDEGE R, Okuma J, Kivuma B, Magnolini R, et al
    Stigma, depression and pillbox return among adults living with HIV in rural Tanzania: A prospective cohort study.
    HIV Med. 2025 Aug 5. doi: 10.1111/hiv.70090.
    PubMed     Abstract available


  138. ROSEN C, Gill MJ, Fujiwara E, Krentz H, et al
    Changing prevalence and risk factors for Toxoplasma gondii seropositivity and disease in persons with HIV at the Southern Alberta Clinic since 1985.
    HIV Med. 2025 Aug 4. doi: 10.1111/hiv.70093.
    PubMed     Abstract available


  139. MEYER SC, Klein Z, Schoepf IC, Thorball CW, et al
    Leukocyte count and new-onset diabetes mellitus in people with HIV: A longitudinal study.
    HIV Med. 2025 Aug 1. doi: 10.1111/hiv.70089.
    PubMed     Abstract available


    July 2025

  140. Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe.
    HIV Med. 2025 Jul 31. doi: 10.1111/hiv.70070.
    PubMed     Abstract available


  141. MBUAGBAW L, Logie CH, Thabane L, Smaill F, et al
    The association between HIV drug resistance testing, viral suppression and mortality in Ontario: a retrospective cohort study.
    HIV Med. 2025 Jul 31. doi: 10.1111/hiv.70086.
    PubMed     Abstract available


  142. BROWN AE, Shah A, Martin V, Chau C, et al
    People diagnosed with HIV before continuing care in England are extremely unlikely to pass on HIV in England.
    HIV Med. 2025 Jul 31. doi: 10.1111/hiv.70084.
    PubMed    


  143. MORAPEDI B, Molefe-Baikai OJ, Hiri O, Kebotsamang K, et al
    Cardiovascular risk knowledge stratified by predicted cardiovascular risk level among people living with HIV attending a tertiary HIV care centre in Gaborone, Botswana: A cross-sectional study.
    HIV Med. 2025 Jul 28. doi: 10.1111/hiv.70088.
    PubMed     Abstract available


  144. HAENGGI K, Mokebe M, Motaboli L, Chakela MG, et al
    The peripartum viral load cascade and outcomes of infants exposed to HIV in Lesotho.
    HIV Med. 2025 Jul 26. doi: 10.1111/hiv.70082.
    PubMed     Abstract available


  145. FITTIPALDI J, Cardoso SW, Nunes EP, De Almeida CF, et al
    Metabolic dysfunction-associated liver disease predicts incident liver fibrosis in people with HIV mono-infection: A cohort study.
    HIV Med. 2025 Jul 23. doi: 10.1111/hiv.70079.
    PubMed     Abstract available


  146. COPAJA-CORZO C, Ticona-Tina D, Caira-Chuquineyra B, Fernandez-Guzman D, et al
    Aetiology of fever of unknown origin in people living with HIV: A systematic review and meta-analysis.
    HIV Med. 2025 Jul 21. doi: 10.1111/hiv.70080.
    PubMed     Abstract available


  147. PASIN C, Orkin C
    Editorial comment on: Gender equality in leadership of HIV care cascade clinical trials: A methodological study.
    HIV Med. 2025 Jul 17. doi: 10.1111/hiv.70076.
    PubMed    


  148. SABIN CA, Barber TJ, Waters L, Mackie N, et al
    CROI 2025 BHIVA working group summary.
    HIV Med. 2025 Jul 16. doi: 10.1111/hiv.70077.
    PubMed    


  149. OKHAI H, Sabin CA
    Response to letter by Kumar et al. on "Exploring the cascade of mental health care among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study".
    HIV Med. 2025 Jul 16. doi: 10.1111/hiv.70081.
    PubMed    


  150. DEL CASTILLO JG, Espinosa B, Cabrera N, Moreno MTS, et al
    Impact of three different interventions designed to improve the implementation of an opt-in targeted strategy of HIV testing in emergency departments.
    HIV Med. 2025 Jul 15. doi: 10.1111/hiv.70074.
    PubMed     Abstract available


  151. KIRILLOVA I, Orhun NM
    Trends in HIV/AIDS cases in Kyrgyzstan between 2012 and 2022: An ecological study.
    HIV Med. 2025 Jul 14. doi: 10.1111/hiv.70078.
    PubMed     Abstract available


  152. WYEN C, Sabranski M, Jonsson-Oldenbuttel C, Bogner J, et al
    Effectiveness of switching to doravirine-based antiretroviral therapy: A real-world study in Germany.
    HIV Med. 2025 Jul 4. doi: 10.1111/hiv.70061.
    PubMed     Abstract available


  153. BASIIMA J, Ssempijja V, Ndyanabo A, Bua GM, et al
    Retention outcomes during same-day antiretroviral therapy initiation in health facilities and outreach settings of Rakai, Uganda, 2016-2021.
    HIV Med. 2025 Jul 4. doi: 10.1111/hiv.70064.
    PubMed     Abstract available


  154. MENDES DE LEON KF, Moody K, Nellen JF, van Vugt M, et al
    Mode of administration matters: Willingness of people with HIV to switch to future long-acting treatments, and health care professionals' intention to discuss these options.
    HIV Med. 2025 Jul 2. doi: 10.1111/hiv.70066.
    PubMed     Abstract available


  155. VINAY D, Jayaweera I, Bowman M, Wijeratne DTD, et al
    Patient-reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long-acting injections as antiretroviral therapy: A systematic review.
    HIV Med. 2025 Jul 2. doi: 10.1111/hiv.70058.
    PubMed     Abstract available


  156. RAMADAN HK, Salah AE, Mohamed ZR, Ayoub A, et al
    False-positive reactivity of fourth-generation HIV enzyme immunoassay caused by COVID-19 and other infections.
    HIV Med. 2025 Jul 1. doi: 10.1111/hiv.70069.
    PubMed     Abstract available


  157. MAZZITELLI M, Leoni D, Campagnolo E, Cozzolino C, et al
    Anal cancer screening in a cohort of women with HIV: Uptake and outcomes from a prospective study in Northern Italy.
    HIV Med. 2025 Jul 1. doi: 10.1111/hiv.70068.
    PubMed     Abstract available


    June 2025
  158. MAZZITELLI M, Trunfio M, Dube K, Lopez AM, et al
    Measuring HIV knowledge and attitudes in the health care setting: Italian results from an ECDC/EACS survey.
    HIV Med. 2025 Jun 26. doi: 10.1111/hiv.70067.
    PubMed     Abstract available


  159. GHOSN J, Chow J, Gandhi M, Gorgolas M, et al
    Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus-1 (HIV-1): A systematic literature review of clinical and patient-reported outcomes.
    HIV Med. 2025 Jun 26. doi: 10.1111/hiv.70065.
    PubMed     Abstract available


  160. GHAZALI MI, Zaki RA, Danaee M
    Late diagnosis of human immunodeficiency virus (HIV) and its associated factors in Asian countries: A systematic review.
    HIV Med. 2025 Jun 25. doi: 10.1111/hiv.70046.
    PubMed     Abstract available


  161. REZENE F, Amoyaw B, Rodrigues M, Ofori S, et al
    Gender equality in leadership of HIV care cascade clinical trials: A methodological study.
    HIV Med. 2025 Jun 20. doi: 10.1111/hiv.70062.
    PubMed     Abstract available


  162. KAYA A, Benke D, Swan T, Breitschwerdt S, et al
    Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?
    HIV Med. 2025 Jun 16. doi: 10.1111/hiv.70063.
    PubMed    


  163. RING K, Elias A, Devonald M, Smuk M, et al
    Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV.
    HIV Med. 2025 Jun 13. doi: 10.1111/hiv.70057.
    PubMed     Abstract available


  164. NILSSON J, Elvstam O, Sorstedt E, Wagner P, et al
    Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register-based study.
    HIV Med. 2025 Jun 12. doi: 10.1111/hiv.70059.
    PubMed     Abstract available


  165. DEBROY P, Pike F, Gawrieh S, Corey KE, et al
    Circulating fibroblast growth factor 21 and growth differentiation factor 15 are associated with severity of hepatic steatosis in people with HIV.
    HIV Med. 2025 Jun 11. doi: 10.1111/hiv.70060.
    PubMed     Abstract available


  166. OKHAI H, Baskaran A, Bukasa L, Peters H, et al
    Changes in characteristics and HIV-clinical outcomes of pregnant people living with HIV in the UK.
    HIV Med. 2025 Jun 10. doi: 10.1111/hiv.70056.
    PubMed     Abstract available


  167. BALLIF M, Correia da Silva Saude M, Haerry D, Stoeckle M, et al
    Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV: A feasibility survey.
    HIV Med. 2025 Jun 8. doi: 10.1111/hiv.70053.
    PubMed     Abstract available


  168. VACCARI LC, Ming DK, Hazell J, Hunter A, et al
    Causes of death in people living with HIV from a North London cohort between 2006 and 2023: A descriptive analysis.
    HIV Med. 2025 Jun 4. doi: 10.1111/hiv.70054.
    PubMed     Abstract available


  169. CHIU SC, Wei LC
    Enhancing sexually transmitted and blood-borne infection prevention in opioid-agonist therapy programmes: Lessons from a canadian pragmatic trial and implications for Taiwan.
    HIV Med. 2025 Jun 2. doi: 10.1111/hiv.70055.
    PubMed    


    May 2025
  170. DOUTRE M, Godin MP, Dmitriev I, Pena-Gralle AP, et al
    Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.
    HIV Med. 2025 May 28. doi: 10.1111/hiv.70051.
    PubMed     Abstract available


  171. RASHID I, Unger NR, Willis C, Dhippayom T, et al
    Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppres
    HIV Med. 2025 May 27. doi: 10.1111/hiv.70050.
    PubMed     Abstract available


  172. SAMANTHA PC, Eduardo PA, Adrian CO
    The silent crisis: Vertical HIV transmission and the struggle for antiretroviral access.
    HIV Med. 2025 May 26. doi: 10.1111/hiv.70052.
    PubMed     Abstract available


  173. KOKORELIAS KM, Valentine D, Eaton AD, Dove E, et al
    "They didn't think we'd live this long": A qualitative exploration of older adults living with HIV perspectives on geriatric care in Ontario.
    HIV Med. 2025 May 22. doi: 10.1111/hiv.70047.
    PubMed     Abstract available


  174. CARTIER A, Milinkovic A, Goodall L, Mora-Peris B, et al
    HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70045.
    PubMed     Abstract available


  175. DIRAJLAL-FARGO S, Nyathi M, Sun S, Bonner LB, et al
    Metabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort (CTAAC)-Heart study.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70049.
    PubMed     Abstract available


  176. FREER GB, Cooper J, Nirantharakumar K, Thomas GN, et al
    Trends in prevalence of anaemia among people living with HIV in the UK: 20 cross-sectional analyses using population-based electronic primary healthcare records.
    HIV Med. 2025 May 21. doi: 10.1111/hiv.70044.
    PubMed     Abstract available


  177. MENDEZ-LOPEZ A, Burns F, Sullivan A, Deogan C, et al
    Knowledge about biomedical HIV prevention among healthcare workers: A cross-sectional study in Europe and Central Asia.
    HIV Med. 2025 May 19. doi: 10.1111/hiv.70048.
    PubMed     Abstract available


  178. VAN BECKHOVEN D, Serrien B, Demeester R, Van Praet J, et al
    Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022.
    HIV Med. 2025 May 12. doi: 10.1111/hiv.70027.
    PubMed     Abstract available


  179. SCHULZ-MEDINA SE, Tapia-Trejo D, Matias-Florentino M, Lopez-Sanchez DM, et al
    HIV molecular network in Mexico City (2021-2022): Understanding transmission dynamics through the role of newly diagnosed cases.
    HIV Med. 2025 May 7. doi: 10.1111/hiv.70029.
    PubMed     Abstract available


  180. JONES HT, Lynch L, Barber TJ, Rattue M, et al
    What services, interventions and support are available for People with HIV in England to manage their overall health and wellbeing? A scoping review.
    HIV Med. 2025 May 7. doi: 10.1111/hiv.70041.
    PubMed     Abstract available


  181. COTA MEDEIROS F, Mendez-Lopez A, Correia de Abreu R, Sarmento E Castro R, et al
    Knowledge and HIV-related stigma among Portuguese healthcare professionals: A cross-sectional analysis.
    HIV Med. 2025 May 7. doi: 10.1111/hiv.70039.
    PubMed     Abstract available


  182. ATALAY S, Mert K, Caglayan D, Sonmez U, et al
    Factors affecting treatment adherence in people with HIV - A single-Centre Descriptive Study from Turkey.
    HIV Med. 2025 May 6. doi: 10.1111/hiv.70042.
    PubMed     Abstract available


  183. POVSHEDNA T, Swann SA, Silva MAP, Tognazzini S, et al
    Self-reported HIV viral load is reliable and not affected by adverse lived experiences of women living with HIV in British Columbia.
    HIV Med. 2025 May 6. doi: 10.1111/hiv.70035.
    PubMed     Abstract available


  184. MENDES-FERREIRA AAC, Beber AMB, da Silveira LN, Guarabyra ASD, et al
    Assessment of compliance with recommendations for HIV perinatal transmission prevention, timely diagnosis and early treatment of children living with HIV in Brazil.
    HIV Med. 2025 May 6. doi: 10.1111/hiv.70038.
    PubMed     Abstract available


  185. LAPO-TALLEDO GJ, Zamora Cevallos AL, Arteaga Reyes CR, Sanchez Redroban JD, et al
    HIV disease hospitalizations and factors associated with in-hospital mortality in Ecuador: A nationwide analysis from 2015 to 2023.
    HIV Med. 2025 May 4. doi: 10.1111/hiv.70040.
    PubMed     Abstract available


  186. MOKADDAM M, Kronfli N, Sheehan NL, Gonzalez Reyes A, et al
    Antiretroviral therapy use, self-reported adherence, and viral suppression among women living with HIV in Canada.
    HIV Med. 2025 May 2. doi: 10.1111/hiv.70034.
    PubMed     Abstract available


  187. NAKAGAWA F, Palich R, Kall M, Sewell J, et al
    Impact of COVID-19 and factors associated with long COVID and COVID-19 vaccine uptake in people with HIV in the United Kingdom: Results from Positive Voices 2022.
    HIV Med. 2025 May 1. doi: 10.1111/hiv.70026.
    PubMed     Abstract available


  188. MAZZITELLI M, Petrara MR, Cozzolino C, Sasset L, et al
    Immune profiles and HIV reservoir in people switching to long-acting cabotegravir/rilpivirine: Findings from a real-life prospective study.
    HIV Med. 2025 May 1. doi: 10.1111/hiv.70030.
    PubMed     Abstract available


    April 2025
  189. DE VITO A, Tavelli A, Cozzi-Lepri A, Giacomelli A, et al
    Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort.
    HIV Med. 2025 Apr 28. doi: 10.1111/hiv.70037.
    PubMed     Abstract available


  190. QUISIAS J, Gill MJ, Coburn SB, Krentz HB, et al
    Cytomegalovirus serostatus among people with HIV, characterizing the prevalence, risk factors, and association with immune recovery.
    HIV Med. 2025 Apr 28. doi: 10.1111/hiv.70036.
    PubMed     Abstract available


  191. IRELAND AT, Ward J, Dolby H, Lawrence C, et al
    Using an automated decision support tool to improve HIV prescribing: A feasibility study.
    HIV Med. 2025 Apr 24. doi: 10.1111/hiv.70028.
    PubMed     Abstract available


  192. XIAO M, Shi Y, Lao Y, Ma Y, et al
    HCV incidence in people with HIV in southwest China: A retrospective cohort study (2004-2023).
    HIV Med. 2025 Apr 19. doi: 10.1111/hiv.70033.
    PubMed     Abstract available



  193. Correction to "Perception of medical care among women living with HIV aged 40 years or older-a European-wide survey".
    HIV Med. 2025 Apr 14. doi: 10.1111/hiv.70032.
    PubMed    


  194. ADMASSU Z, Logie CH, Vahedi L, Underhill A, et al
    Longitudinal associations between social determinants of health and well-being among women living with HIV in Canada: A latent class analysis.
    HIV Med. 2025 Apr 14. doi: 10.1111/hiv.70031.
    PubMed     Abstract available


  195. BARDA B, Barilaro G, Bellini P, Turicchi G, et al
    Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.
    HIV Med. 2025 Apr 9. doi: 10.1111/hiv.70025.
    PubMed     Abstract available


  196. ZUBAIR A, Ahmad H, Arif MM, Ali M, et al
    mRNA vaccines against HIV: Hopes and challenges.
    HIV Med. 2025 Apr 7. doi: 10.1111/hiv.70024.
    PubMed     Abstract available


  197. ZHAO J, Gao M, Zhao D, Tian W, et al
    Prevalence of late HIV diagnosis and its impact on mortality: A comprehensive systematic review and meta-analysis.
    HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70023.
    PubMed     Abstract available


  198. CHACHU KH, Maboe KA
    Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.
    HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70022.
    PubMed     Abstract available



  199. BHIVA Spring Conference 2025, 23 April - 25 April 2025, Brighton, UK.
    HIV Med. 2025;26 Suppl 2:17-137.
    PubMed    



  200. BHIVA Spring Conference 2025, 23 April - 25 April 2025, Brighton, UK.
    HIV Med. 2025;26 Suppl 2:3-16.
    PubMed    


    March 2025
  201. BARTOVSKA Z, Massmann R, Jilich D, Groh T, et al
    Late diagnosis of HIV among Ukrainian refugees in the Czech Republic: A retrospective, observational study.
    HIV Med. 2025 Mar 29. doi: 10.1111/hiv.70021.
    PubMed     Abstract available


  202. AKSAK-WAS B, Skonieczna-Zydecka K, Parczewski M, Hrynkiewicz R, et al
    Rethinking HIV treatment: How non-integrase strand regimens may hold the key to better immune health.
    HIV Med. 2025 Mar 28. doi: 10.1111/hiv.70020.
    PubMed     Abstract available


  203. MOSHI LS, Okuma J, Luoga E, Kalinjuma AV, et al
    Trends of severe HIV disease and mortality among children in rural Tanzania.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70015.
    PubMed     Abstract available


  204. SAUMOY M, Fernandez A, Tiraboschi J, Penafiel J, et al
    Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70017.
    PubMed     Abstract available


  205. VASELLI NM, Salaveria K, Winearls J, Garnham K, et al
    Pneumocystis jirovecii pneumonia-Immune reconstitution inflammatory syndrome: A review of published cases.
    HIV Med. 2025 Mar 24. doi: 10.1111/hiv.70016.
    PubMed     Abstract available


  206. MARTORELL C, Ramgopal M, Hagins D, Osiyemi O, et al
    Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
    HIV Med. 2025 Mar 21. doi: 10.1111/hiv.70018.
    PubMed     Abstract available


  207. PINCUS KJ, Faridi N, Ryscavage PA, Seung H, et al
    Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use.
    HIV Med. 2025 Mar 20. doi: 10.1111/hiv.70019.
    PubMed     Abstract available


  208. HERNANDEZ-TRUJILLO PN, Lopez-Baron CA, Arevalo-Pinzon G, Trujillo-Guiza ML, et al
    Taxonomic and functional profile of the anorectal microbiota in HIV-positive and HIV-negative men who have sex with men, using a metagenomic approach.
    HIV Med. 2025 Mar 18. doi: 10.1111/hiv.70014.
    PubMed     Abstract available


  209. CHAWLA S, Kaida A, Brouillette MJ, Kleiner B, et al
    Impact of mental health service use on the HIV care cascade among women.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.70008.
    PubMed     Abstract available


  210. SURIYARACHCHI DDC, Katuwavila NP
    Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.13770.
    PubMed     Abstract available


  211. HE X, Zheng W, Wang X, Jiang Y, et al
    Trend of HIV/AIDS disease burden in China from 1990 to 2021: An age-period-cohort model analysis.
    HIV Med. 2025 Mar 4. doi: 10.1111/hiv.70009.
    PubMed     Abstract available



  212. DOAK 2025 / 12th German-Austrian AIDS Congress, 20-22 March 2025, Hofburg Vienna.
    HIV Med. 2025;26 Suppl 1:3-82.
    PubMed    


    February 2025
  213. GIFFORD AJ, Jaspal R, Jones BA, McDermott DT, et al
    Predicting PrEP acceptability and self-efficacy among men who have sex with men in the UK: The roles of identity resilience, science mistrust, and stigma.
    HIV Med. 2025 Feb 27. doi: 10.1111/hiv.13768.
    PubMed     Abstract available


  214. HENDERSON M, Lyons D, Beddows S, Cowen M, et al
    High-risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.70001.
    PubMed     Abstract available


  215. BEGUELIN C, Surial B, Hofmann E, Begre L, et al
    Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection.
    HIV Med. 2025 Feb 25. doi: 10.1111/hiv.13766.
    PubMed     Abstract available


  216. BLANCH J, Martinez E, Mena A, Duenas C, et al
    Impact of training healthcare professionals in the detection and management of neuropsychiatric comorbidities in people with HIV: The CONECTAR project in Spain.
    HIV Med. 2025 Feb 24. doi: 10.1111/hiv.70002.
    PubMed     Abstract available


  217. ELKHEIR N, Dominic C, Price A, Carter J, et al
    HIV in Latin American migrants in the UK: A neglected population in the 95-95-95 targets.
    HIV Med. 2025 Feb 24. doi: 10.1111/hiv.70007.
    PubMed     Abstract available


  218. YU S, MacGibbon J, Bavinton B, Smith AKJ, et al
    Associations between country of birth, migration status and engagement in HIV care among gay and bisexual men living with HIV in Australia, 2019-2022.
    HIV Med. 2025 Feb 19. doi: 10.1111/hiv.13769.
    PubMed     Abstract available


  219. AKASHANAND, Khatib MN, Serhan HA, Jena D, et al
    Spatial and temporal trends in HIV/AIDS burden among South Asian countries from 1990 to 2021: A systematic examination of the Global Burden of Disease study 2021.
    HIV Med. 2025 Feb 19. doi: 10.1111/hiv.70003.
    PubMed     Abstract available


  220. MEDINA N, Alastruey-Izquierdo A, Bonilla O, Mercado D, et al
    Patients re-engaging with HIV care in Guatemala: Prioritizing CD4 counting and screening for histoplasmosis and tuberculosis.
    HIV Med. 2025 Feb 17. doi: 10.1111/hiv.70000.
    PubMed     Abstract available


  221. SADIQ E, Woodiwiss A, Tade G, Nel J, et al
    The role of atherosclerosis in HIV-associated vasculopathy in young South African stroke patients.
    HIV Med. 2025 Feb 13. doi: 10.1111/hiv.13764.
    PubMed     Abstract available


  222. NAZARENKO N, Chen YY, Borkowski P, Biavati L, et al
    Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
    HIV Med. 2025 Feb 13. doi: 10.1111/hiv.13760.
    PubMed     Abstract available


  223. KUMAR S, Mehta R, Sah R, Verma A, et al
    Commentary on 'Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study'.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13767.
    PubMed    


  224. YANG Q, Zhou J, Lan G, Qin Q, et al
    Factors influencing the quality of life and social skills of children living with HIV: A case-control study.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13758.
    PubMed     Abstract available


  225. SALVO PF, Ciccullo A, Visconti E, Lombardi F, et al
    Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir.
    HIV Med. 2025 Feb 5. doi: 10.1111/hiv.13765.
    PubMed     Abstract available


    January 2025
  226. PINAR SS, Manak M, Saravanan S, Imami N, et al
    Point-of-care nucleic acid testing - a step forward in controlling the HIV epidemic: A review.
    HIV Med. 2025 Jan 25. doi: 10.1111/hiv.13757.
    PubMed     Abstract available


  227. ODONGPINY EAL, Nicol M, Katana E, Owori J, et al
    A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda.
    HIV Med. 2025 Jan 24. doi: 10.1111/hiv.13761.
    PubMed     Abstract available


  228. IZQUIERDO R, Suarez-Garcia I, Marco-Sanchez C, Perez-Latorre L, et al
    Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
    HIV Med. 2025 Jan 21. doi: 10.1111/hiv.13762.
    PubMed     Abstract available


  229. MKHIZE N, Garrido J, Cole-Haley S, Diallo DD, et al
    Breaking down global barriers: A multinational and multi-community approach to combat stigma and enhance mental wellbeing in people with HIV.
    HIV Med. 2025 Jan 16. doi: 10.1111/hiv.13763.
    PubMed     Abstract available


  230. MCGARRITY MW, MacPherson P, Li A, Naccarato M, et al
    Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery.
    HIV Med. 2025 Jan 15. doi: 10.1111/hiv.13759.
    PubMed     Abstract available


  231. WALKER SH, Grierson J, Sullivan A, Alagaratnam J, et al
    The effects of the COVID-19 pandemic on people living with HIV.
    HIV Med. 2025 Jan 6. doi: 10.1111/hiv.13754.
    PubMed     Abstract available


  232. HU T, Yang S, Yu J, Yang Z, et al
    Transitions in treatment: A systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders.
    HIV Med. 2025 Jan 2. doi: 10.1111/hiv.13756.
    PubMed     Abstract available


    December 2024
  233. VARMA A, Singh MP, Sah S, Verma A, et al
    Commentary on 'DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy'.
    HIV Med. 2024 Dec 26. doi: 10.1111/hiv.13755.
    PubMed    


  234. SANDULESCU O, Moseholm E
    Editorial comment on: "It's like it's the old boys Club: The age-related experiences of diverse older women living with HIV: A scoping review and consultative exercise".
    HIV Med. 2024 Dec 22. doi: 10.1111/hiv.13750.
    PubMed    


  235. OKHAI H, Winston A, Post F, Boffito M, et al
    Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study.
    HIV Med. 2024 Dec 19. doi: 10.1111/hiv.13753.
    PubMed     Abstract available


  236. MIRON VD, Sabin CA, Sandulescu O, Lourida G, et al
    Perception of medical care among women living with HIV aged 40 years or older-A European-wide survey.
    HIV Med. 2024 Dec 15. doi: 10.1111/hiv.13749.
    PubMed     Abstract available


  237. KOKORELIAS KM, Su E, Brown P, McKinlay S, et al
    "It's like it's the old boys club"-the age-related experiences of diverse older women living with HIV: A scoping review and consultative exercise.
    HIV Med. 2024 Dec 12. doi: 10.1111/hiv.13751.
    PubMed     Abstract available


  238. BARRE T, Ramier C, Ory K, Sogni P, et al
    Transient CD4 cell recovery after hepatitis C virus cure in HIV/hepatitis C virus coinfected patients (ANRS CO13 HEPAVIH cohort).
    HIV Med. 2024 Dec 11. doi: 10.1111/hiv.13752.
    PubMed    


  239. ALFORD K, Sidat S, Bristowe K, Cicconi P, et al
    Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.
    HIV Med. 2024 Dec 10. doi: 10.1111/hiv.13748.
    PubMed     Abstract available


  240. FALCI DR, Pasqualotto AC, Vieceli T, Sued O, et al
    Performance of urine Xpert MTB/RIF ultra in a tuberculosis screening strategy in hospitalized patients with advanced HIV disease: Results from an implementation initiative in Brazil.
    HIV Med. 2024 Dec 10. doi: 10.1111/hiv.13746.
    PubMed     Abstract available


  241. SZETELA B, Bozejko M, Szymczak A, Giniewicz K, et al
    Rapid HIV pre-exposure prophylaxis (PrEP) initiation is safe and feasible: Experience from Wroclaw All Saints cohort in Poland 2017-2021.
    HIV Med. 2024 Dec 5. doi: 10.1111/hiv.13747.
    PubMed     Abstract available


  242. D'ARMINIO MONFORTE A, Tavelli A, Quiros-Roldan E, Fabbiani M, et al
    Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naive and ART-experienced people with HIV in real-world setting: Data from the Icona cohort.
    HIV Med. 2024 Dec 2. doi: 10.1111/hiv.13740.
    PubMed     Abstract available


  243. NELSON M, Bracchi M, Hunter E, Ong E, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of non-tuberculous mycobacteria 2024.
    HIV Med. 2024;25 Suppl 4:3-25.
    PubMed    


    November 2024
  244. OJUKWU E, Pashaei A, Maia JC, Omobhude OF, et al
    Impact of the COVID-19 pandemic on the HIV care continuum and associated factors in middle-income countries: A mixed-methods systematic review.
    HIV Med. 2024 Nov 28. doi: 10.1111/hiv.13739.
    PubMed     Abstract available


  245. JONES HT, Barber TJ
    A qualitative study of perspectives, experiences and priority outcomes for people living with HIV and frailty: Editorial comment on: "We are fragile, but we are strong": Navigating Frailty and HIV in Aging Populations: Perspectives on Language, Stigma
    HIV Med. 2024 Nov 28. doi: 10.1111/hiv.13736.
    PubMed    


  246. YU X, Kuo YF, Dike AA, Efejuku T, et al
    Trends and disparities in antiretroviral therapy prescription rates among US Medicare beneficiaries with HIV.
    HIV Med. 2024 Nov 25. doi: 10.1111/hiv.13745.
    PubMed     Abstract available


  247. BARBOSU CM, Avirvarei C, Manciuc C, Dye T, et al
    Stigma-associated attitudes and practices among Romanian clinical providers.
    HIV Med. 2024 Nov 25. doi: 10.1111/hiv.13742.
    PubMed     Abstract available


  248. BLANCO JR, Gonzalez-Baeza A, Martinez-Vicente A, Albendin-Iglesias H, et al
    Loneliness and social isolation in people with HIV aged >/=50 years. The No One Alone (NOA)-GeSIDA study conducted by the GeSIDA 12021 study group.
    HIV Med. 2024 Nov 22. doi: 10.1111/hiv.13743.
    PubMed     Abstract available


  249. PENNER J, Ombajo LA, Nkuranga J, Otieno E, et al
    High prevalence of osteoporosis among virally suppressed older people (>/=60 years) living with HIV.
    HIV Med. 2024 Nov 21. doi: 10.1111/hiv.13741.
    PubMed     Abstract available


  250. BAKEWELL N, Kanitkar T, Dissanayake O, Symonds M, et al
    Comparing short-term mortality between people with and without HIV admitted to the intensive care unit: A single-centre matched cohort study (2000-2019).
    HIV Med. 2024 Nov 20. doi: 10.1111/hiv.13737.
    PubMed     Abstract available


  251. METCALFE R, Fraser R, Trayner KMA, Glancy M, et al
    Rising mortality among people who inject drugs living with HIV in Scotland, UK: A 20-year retrospective cohort study.
    HIV Med. 2024 Nov 18. doi: 10.1111/hiv.13733.
    PubMed     Abstract available


  252. KENIYOPOULLOS R, Khawaja AA, Boffito M, Emerson M, et al
    In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors.
    HIV Med. 2024 Nov 15. doi: 10.1111/hiv.13738.
    PubMed     Abstract available


  253. BLAKEY EG, Fairhead CEL, Rodger AJ, Burns FM, et al
    Clinical staff attitudes towards opt-out consent for blood-borne virus screening in emergency departments in England.
    HIV Med. 2024 Nov 13. doi: 10.1111/hiv.13735.
    PubMed     Abstract available


  254. RODKJAER LO, Storgaard M, Schougaard LMV
    Implementation of patient-reported outcomes for people living with HIV: Insights from patients and healthcare providers in a Danish outpatient clinic.
    HIV Med. 2024 Nov 13. doi: 10.1111/hiv.13734.
    PubMed     Abstract available


  255. SEMPERE A, Gonzalez-Rioja X, Martinez E
    AI in medicine: No longer the future, but the present.
    HIV Med. 2024 Nov 11. doi: 10.1111/hiv.13732.
    PubMed    


  256. LAGUNO M, de Lazzari E, Berrocal L, Inciarte A, et al
    Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV.
    HIV Med. 2024 Nov 7. doi: 10.1111/hiv.13730.
    PubMed     Abstract available


  257. ABGRALL S, Selinger-Leneman H, Lanoy E, Becker A, et al
    Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH).
    HIV Med. 2024 Nov 4. doi: 10.1111/hiv.13729.
    PubMed     Abstract available


    October 2024
  258. STEPHAN C, Spinner CD, Rieke A, Christensen S, et al
    Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
    HIV Med. 2024 Oct 30. doi: 10.1111/hiv.13728.
    PubMed     Abstract available


  259. WATERS L, Martinez E
    Cardiovascular prevention: Statins and beyond-A message from the editors of the special issue of HIV medicine.
    HIV Med. 2024 Oct 29. doi: 10.1111/hiv.13731.
    PubMed    


  260. HICKS WL, Khalil S, Burke FW, Ho MQ, et al
    Comparison of risk factors and mortality in veterans with HIV and those without HIV suffering first major acute cardiovascular events.
    HIV Med. 2024 Oct 27. doi: 10.1111/hiv.13724.
    PubMed     Abstract available


  261. IZQUIERDO R, Suarez-Garcia I, Gomez-Garcia T, Marco-Sanchez C, et al
    Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
    HIV Med. 2024 Oct 25. doi: 10.1111/hiv.13726.
    PubMed     Abstract available


  262. FERNANDES G, Chappell E, Goetghebuer T, Kahlert CR, et al
    HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey.
    HIV Med. 2024 Oct 23. doi: 10.1111/hiv.13723.
    PubMed     Abstract available


  263. FONSECA F, Avelino-Silva VI, Odoke W, van den Hombergh J, et al
    Are people with HIV at advanced disease stages being left behind? A global survey.
    HIV Med. 2024 Oct 18. doi: 10.1111/hiv.13725.
    PubMed     Abstract available


  264. CLAIR-SULLIVAN NS, Vera JH, Maddocks M, Harding R, et al
    'We are fragile, but we are strong': A qualitative study of perspectives, experiences and priority outcomes for people living with HIV and frailty.
    HIV Med. 2024 Oct 13. doi: 10.1111/hiv.13722.
    PubMed     Abstract available


  265. MA Y, Achiche S, Tu G, Vicente S, et al
    The first AI-based Chatbot to promote HIV self-management: A mixed methods usability study.
    HIV Med. 2024 Oct 10. doi: 10.1111/hiv.13720.
    PubMed     Abstract available


  266. ERON JJ, Ramgopal M, Osiyemi O, Mckellar M, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.
    HIV Med. 2024 Oct 6. doi: 10.1111/hiv.13721.
    PubMed     Abstract available


  267. TRAYNER KMA, Palmateer NE, McAuley A, Yeung A, et al
    Examining trends in the incidence of HIV infection among people with a history of drug use to inform an outbreak investigation and response: A retrospective cohort study.
    HIV Med. 2024 Oct 4. doi: 10.1111/hiv.13712.
    PubMed     Abstract available


  268. PLATTEAU T, Herrijgers C, Barvaux V, Vanden Berghe W, et al
    Chemsex and its impact on gay and bisexual men who have sex with men: Findings from an online survey in Belgium.
    HIV Med. 2024 Oct 3. doi: 10.1111/hiv.13717.
    PubMed     Abstract available


    September 2024
  269. GUTIERREZ F
    "Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study".
    HIV Med. 2024 Sep 27. doi: 10.1111/hiv.13719.
    PubMed    


  270. NIMKAR S, Kinikar A, Mave V, Khol V, et al
    Long-term risk of mortality and loss to follow-up in children and adolescents on antiretroviral therapy in Asia.
    HIV Med. 2024 Sep 26. doi: 10.1111/hiv.13718.
    PubMed     Abstract available


  271. MENDES-FERREIRA AAC, Veras NMC, Pinho REGG, Pascom AR, et al
    HIV drug resistance, viral suppression, and survival in children living with HIV in Brazil.
    HIV Med. 2024 Sep 25. doi: 10.1111/hiv.13714.
    PubMed     Abstract available


  272. NAZARETH J, Adebayo A, Fahad M, Karim H, et al
    Cardiovascular medication adherence testing in patients living with HIV: A single-centre observational study.
    HIV Med. 2024 Sep 24. doi: 10.1111/hiv.13715.
    PubMed     Abstract available


  273. MANYARA AM, Manyanga T, Burton A, Wilson H, et al
    Prevalence, factors and quality of life associated with frailty and pre-frailty in middle-aged and older adults living with HIV in Zimbabwe: A cross-sectional study.
    HIV Med. 2024 Sep 20. doi: 10.1111/hiv.13716.
    PubMed     Abstract available


  274. FAROOQ HZ, Whitton L, Mwendera C, Divall P, et al
    Virtual care pathways for people living with HIV: A mixed-methods systematic review.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13701.
    PubMed     Abstract available


  275. WOODS J, Sokhela S, Akpomiemie G, Bosch B, et al
    DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.
    HIV Med. 2024 Sep 17. doi: 10.1111/hiv.13711.
    PubMed     Abstract available


  276. DAY S, Rae C, McOwan A, Wilkins R, et al
    Patient evaluation of Klick, a technology-enabled, nurse-delivered HIV outpatient pathway.
    HIV Med. 2024 Sep 15. doi: 10.1111/hiv.13710.
    PubMed     Abstract available



  277. Correction to "Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis".
    HIV Med. 2024 Sep 11. doi: 10.1111/hiv.13713.
    PubMed    


  278. BARBER TJ, Clarke A, Fox A, Mackie NE, et al
    CROI 2024 BHIVA working group summary.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13705.
    PubMed     Abstract available


  279. YANG X, Shi F, Zhang H, Giang WA, et al
    Long COVID among people with HIV: A systematic review and meta-analysis.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13708.
    PubMed     Abstract available


  280. PINEIRO C, Policarpo S, Caldas C, Santos L, et al
    Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
    HIV Med. 2024 Sep 6. doi: 10.1111/hiv.13699.
    PubMed     Abstract available


  281. PREVOTEAU DU CLARY F, Majerholc C, Zucman D, Livrozet JM, et al
    Evaluation of HIV antiretroviral treatment adherence in 2019 using anonymized data from the French national health insurance claims data base: The COCOVIH study.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13690.
    PubMed     Abstract available


  282. MCCALL KL, Cabral DL, Coghlan JF, Concepcion AM, et al
    Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13709.
    PubMed     Abstract available


  283. SHU Y, Zhang M, Li J, Deng X, et al
    Trajectories of CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio in patients with HIV and long-term virological suppression based on Yunnan HIV cohort.
    HIV Med. 2024 Sep 2. doi: 10.1111/hiv.13707.
    PubMed     Abstract available


    August 2024
  284. KO S, Dominguez-Dominguez L, Ottaway Z, Campbell L, et al
    Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom.
    HIV Med. 2024 Aug 29. doi: 10.1111/hiv.13706.
    PubMed     Abstract available


  285. URSENBACH A, Sireyjol A, Delpierre C, Duvivier C, et al
    Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study.
    HIV Med. 2024 Aug 28. doi: 10.1111/hiv.13698.
    PubMed     Abstract available


  286. LI N, Thomas L, Allan A, John B, et al
    Optimizing statin prescriptions for people living with HIV: Evidence for improved communication and shared care between primary care and specialist HIV services.
    HIV Med. 2024 Aug 26. doi: 10.1111/hiv.13704.
    PubMed     Abstract available


  287. HSU RK, Brunet L, Lackey PC, Pierone G Jr, et al
    Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study.
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13700.
    PubMed     Abstract available


  288. GRINSPOON SK, Lu MT, Zanni MV, Diggs MR, et al
    What have we learned from the REPRIEVE trial and where do we go from here?
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13703.
    PubMed    


  289. VASHISHT S, Thakur N, Kant S, Rai S, et al
    Assessment of targeted intervention programme under the National AIDS Control Program among men who have sex with men in India.
    HIV Med. 2024 Aug 25. doi: 10.1111/hiv.13702.
    PubMed     Abstract available


  290. SWIFT E, Upton G, Fitzpatrick C, Roberts J, et al
    Impact of omission of routine blood monitoring of stable patients living with HIV during the coronavirus pandemic.
    HIV Med. 2024 Aug 18. doi: 10.1111/hiv.13696.
    PubMed     Abstract available


  291. CHAN CK, Huang SS, Wong KH, Leung CC, et al
    No increased risk of tuberculosis-related immune reconstitution inflammatory syndrome with integrase inhibitor-based antiretroviral therapy in people with HIV with profound immunosuppression.
    HIV Med. 2024 Aug 12. doi: 10.1111/hiv.13695.
    PubMed     Abstract available


  292. WHITE TM, Fuster-RuizdeApodaca MJ, Iniesta C, Prats-Silvestre C, et al
    Network analysis to prioritize issues for intervention to improve the health-related quality of life of people with HIV in Spain.
    HIV Med. 2024 Aug 10. doi: 10.1111/hiv.13693.
    PubMed     Abstract available


  293. BEKELE A, Ahmed I, Tefera F, Yimam JA, et al
    Incidence and predictors of attrition from HIV treatment among adults living with HIV in high-caseload facilities following implementation of universal test and treat strategy in Ethiopia: A prospective cohort study.
    HIV Med. 2024 Aug 6. doi: 10.1111/hiv.13691.
    PubMed     Abstract available


  294. SAH S, Verma A, Zahiruddin QS, Rustagi S, et al
    Commentary on 'Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)'.
    HIV Med. 2024 Aug 1. doi: 10.1111/hiv.13689.
    PubMed    


  295. KABLAWI D, Milic J, Thomas T, Fotsing Tadjo T, et al
    Metabolic dysfunction-associated steatohepatitis exhibits sex differences in people with HIV.
    HIV Med. 2024 Aug 1. doi: 10.1111/hiv.13697.
    PubMed     Abstract available


    July 2024
  296. INESTROZA K, Hurtado V, Larson ME, Satish S, et al
    Characterizing heart failure and its subtypes in people living with HIV.
    HIV Med. 2024 Jul 30. doi: 10.1111/hiv.13694.
    PubMed     Abstract available


  297. PIACENTINI D, Nicolini G, Bugana D, Piccolin G, et al
    Breastfeeding in women living with HIV in high-income countries: It's time to act.
    HIV Med. 2024 Jul 30. doi: 10.1111/hiv.13692.
    PubMed    


  298. SCOFIELD D, Frisch M, Andersson M, Storgaard M, et al
    Psychosocial and sexual health among men with and without HIV who have sex with men: A cross-sectional nationwide study in Denmark.
    HIV Med. 2024 Jul 18. doi: 10.1111/hiv.13688.
    PubMed     Abstract available


  299. RUIZ-BILBAO S, Videla S, Pascual E, Soler M, et al
    Functional and structural neuroretinal disorders in HIV Controllers. Prospective cohort study.
    HIV Med. 2024 Jul 9. doi: 10.1111/hiv.13685.
    PubMed     Abstract available


  300. ZAJDMAN-FAITELSON D, Cardenas-Hernandez ML, Guzman-Bucio S, Camiro-Zuniga A, et al
    Clinicopathological concordance of mucocutaneous manifestations in people living with HIV: A cross-sectional study.
    HIV Med. 2024 Jul 8. doi: 10.1111/hiv.13686.
    PubMed     Abstract available


  301. VERMA A, Pant M, Khatib MN, Singh MP, et al
    Commentary on 'Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities'.
    HIV Med. 2024 Jul 2. doi: 10.1111/hiv.13687.
    PubMed    


    June 2024
  302. SIMOES D, Raben D, Moran AB, Imaz A, et al
    The HepHIV 2023 Madrid conference: A call to action for political leadership in reaching the sustainable development goals on earlier testing and linkage to care for HIV, viral hepatitis, and sexually transmitted infections.
    HIV Med. 2024 Jun 24. doi: 10.1111/hiv.13683.
    PubMed     Abstract available


  303. BARQUET-MUNOZ SA, Lopez-Morales RA, Stier EA, Mejorada-Pulido E, et al
    Prevalence of anal high-risk human papillomavirus (HR-HPV) types in people living with HIV and a history of cancer.
    HIV Med. 2024 Jun 20. doi: 10.1111/hiv.13684.
    PubMed     Abstract available


  304. BASOULIS D, Mastrogianni E, Eliadi I, Papadopoulou M, et al
    HCV-HIV co-infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece.
    HIV Med. 2024 Jun 20. doi: 10.1111/hiv.13681.
    PubMed     Abstract available


  305. LAM JO, Hou CE, Alexeeff S, Levine T, et al
    Clinically recognized sleep disorders in people living with HIV.
    HIV Med. 2024 Jun 18. doi: 10.1111/hiv.13682.
    PubMed     Abstract available


  306. RING K, Smuk M, Shongwe M, Okonta L, et al
    Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
    HIV Med. 2024 Jun 10. doi: 10.1111/hiv.13679.
    PubMed     Abstract available


  307. HUTCHINSON J, Neesgard B, Kowalska J, Grabmeier-Pfistershammer K, et al
    Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men.
    HIV Med. 2024 Jun 5. doi: 10.1111/hiv.13662.
    PubMed     Abstract available


  308. MALAGNINO V, Cozzi-Lepri A, Svicher V, Girardi E, et al
    Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy.
    HIV Med. 2024 Jun 4. doi: 10.1111/hiv.13680.
    PubMed     Abstract available


  309. PASIN C, Nunez DG, Kusejko K, Hachfeld A, et al
    Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.
    HIV Med. 2024 Jun 3. doi: 10.1111/hiv.13677.
    PubMed     Abstract available


    May 2024
  310. CHROMY D, Urban N, Bauer WM, Kreuter A, et al
    Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak.
    HIV Med. 2024 May 30. doi: 10.1111/hiv.13678.
    PubMed     Abstract available


  311. INGILIZ P, Lutz T, Schewe K, Baumgarten A, et al
    Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemic.
    HIV Med. 2024 May 29. doi: 10.1111/hiv.13651.
    PubMed     Abstract available


  312. SCHMIDT AJ, Weatherburn P, Wang H, Lutz T, et al
    Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021.
    HIV Med. 2024 May 27. doi: 10.1111/hiv.13657.
    PubMed     Abstract available


  313. SZCZEPANSKI A, Klesiewicz K, Ankiersztejn-Bartczak M, Drozdz K, et al
    Voluntary counselling and testing points (VCTs) in Poland as a complementary and accessible alternative to public healthcare facilities: A comparative analysis of epidemiological data from the VCTs and the National Institute of Public Health NIH-Natio
    HIV Med. 2024 May 21. doi: 10.1111/hiv.13658.
    PubMed     Abstract available


  314. YANG X, Zhang G, Kang W, Guo J, et al
    Related barriers to using HIV pre-exposure prophylaxis among MSM: A multicentre cross-sectional survey.
    HIV Med. 2024 May 21. doi: 10.1111/hiv.13663.
    PubMed     Abstract available


  315. KATLAMA C, Bisshop F, Bogner J, Perez Elias MJ, et al
    Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
    HIV Med. 2024 May 17. doi: 10.1111/hiv.13643.
    PubMed     Abstract available


  316. LOGIE CH, Sokolovic N, Casale A, Ndung'u M, et al
    Clinical HIV outcome trajectories associated with a history of child protective service out-of-home care: Longitudinal cohort findings with women living with HIV in Canada.
    HIV Med. 2024 May 17. doi: 10.1111/hiv.13660.
    PubMed     Abstract available


  317. LUMBRERAS ARETA M, Migliorelli Falcone FE, Rudin C, Kahlert CR, et al
    Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study.
    HIV Med. 2024 May 16. doi: 10.1111/hiv.13652.
    PubMed     Abstract available


  318. BUSCA-ARENZANA C, Ortega-Gonzalez D, Diaz-Almiron M, Montes ML, et al
    Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.
    HIV Med. 2024 May 15. doi: 10.1111/hiv.13659.
    PubMed     Abstract available


  319. NAKAMURA H, Yamamoto K
    Mpox in people with HIV: A narrative review.
    HIV Med. 2024 May 15. doi: 10.1111/hiv.13661.
    PubMed     Abstract available


  320. BROWN L, Sargent P, Islam M, Downie C, et al
    Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat.
    HIV Med. 2024 May 9. doi: 10.1111/hiv.13656.
    PubMed     Abstract available


  321. FINLAYSON-TRICK E, Tam C, Wang L, Dawydiuk N, et al
    Access to care and impact on HIV treatment interruptions during the COVID-19 pandemic among people living with HIV in British Columbia.
    HIV Med. 2024 May 9. doi: 10.1111/hiv.13654.
    PubMed     Abstract available


  322. MATACOTTA JJ, Tran D, Yoon S
    The prevalence of major depressive disorder in people with HIV: Results from the All of Us Research Program.
    HIV Med. 2024 May 7. doi: 10.1111/hiv.13653.
    PubMed     Abstract available


  323. OOSTERHOF P, de Zoete BGJA, Vanhommerig JW, Langebeek N, et al
    De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study.
    HIV Med. 2024 May 7. doi: 10.1111/hiv.13655.
    PubMed     Abstract available


  324. DOCKRELL DH, Breen R, Collini P, Lipman MCI, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of pulmonary opportunistic infections 2024.
    HIV Med. 2024;25 Suppl 2:3-37.
    PubMed    


  325. GREIG J, Bamford A, Chadwick D, Darley A, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: Considerations in pregnancy 2024.
    HIV Med. 2024;25 Suppl 3:3-19.
    PubMed    


    April 2024
  326. LLIBRE JM, Garcia F, Blanco JL, Pelaez EP, et al
    Prevalence of people living with multidrug-resistant HIV and limited treatment options in Spain.
    HIV Med. 2024 Apr 30. doi: 10.1111/hiv.13650.
    PubMed     Abstract available


  327. DINESHA TR, Boobalan J, Kumar CV, Manikandan P, et al
    HIV-1 low-level viraemia predicts virological failure in first-line and second-line ART-experienced individuals in India: A retrospective longitudinal study.
    HIV Med. 2024 Apr 25. doi: 10.1111/hiv.13641.
    PubMed     Abstract available


  328. BULLO M, Kierszenowicz T, Acosta MC, Rolon MJ, et al
    Telemedicine in HIV health care during the COVID-19 pandemic: An implementation research study in Buenos Aires, Argentina.
    HIV Med. 2024 Apr 24. doi: 10.1111/hiv.13646.
    PubMed     Abstract available


  329. JOHN M, Williams L, Nolan G, Bonnett M, et al
    Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
    HIV Med. 2024 Apr 21. doi: 10.1111/hiv.13647.
    PubMed     Abstract available


  330. DEMA E, Peters H, Gilleece Y, Thorne C, et al
    Residential and healthcare mobility during pregnancy among women living with HIV in the UK, 2009-2019.
    HIV Med. 2024 Apr 10. doi: 10.1111/hiv.13648.
    PubMed     Abstract available


  331. OZHMEGOVA E, Lebedev A, Antonova A, Kuznetsova A, et al
    Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia.
    HIV Med. 2024 Apr 7. doi: 10.1111/hiv.13642.
    PubMed     Abstract available


  332. CALZA L, Giglia M, Colangeli V, Bon I, et al
    Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
    HIV Med. 2024 Apr 3. doi: 10.1111/hiv.13644.
    PubMed     Abstract available



  333. BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
    HIV Med. 2024;25 Suppl 1:21-111.
    PubMed    



  334. BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
    HIV Med. 2024;25 Suppl 1:3-16.
    PubMed    



  335. BHIVA Spring Conference 2024, Birmingham, 29 April - 1 May 2024.
    HIV Med. 2024;25 Suppl 1:17-20.
    PubMed    


    March 2024
  336. LIU Y, Cheng Z, Xian Y, Liu X, et al
    Cascade analysis of awareness, willingness, uptake and adherence with regard to PrEP among young men who have sex with men (YMSM) in China: A comparison between students and non-students.
    HIV Med. 2024 Mar 27. doi: 10.1111/hiv.13639.
    PubMed     Abstract available


  337. OTTAWAY Z, Campbell L, Fox J, Burns F, et al
    HIV outcomes during the COVID-19 pandemic in people of Black ethnicities living with HIV in England.
    HIV Med. 2024 Mar 26. doi: 10.1111/hiv.13640.
    PubMed     Abstract available


  338. SAWRY S, Ayalew K, Maimela G, Briggs-Hagen M, et al
    Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    HIV Med. 2024 Mar 22. doi: 10.1111/hiv.13638.
    PubMed     Abstract available


  339. ZOU S, Chen Z, Tan Y, Tan M, et al
    Microbiomes detected by cerebrospinal fluid metagenomic next-generation sequencing among patients with and without HIV with suspected central nervous system infection.
    HIV Med. 2024 Mar 21. doi: 10.1111/hiv.13634.
    PubMed     Abstract available


  340. SOCIAS ME, Cui Z, Le Foll B, Lei J, et al
    Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial.
    HIV Med. 2024 Mar 20. doi: 10.1111/hiv.13636.
    PubMed     Abstract available


  341. JACOBS TG, Okemo D, Ssebagereka A, Mwehonge K, et al
    Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
    HIV Med. 2024 Mar 18. doi: 10.1111/hiv.13635.
    PubMed     Abstract available


  342. DOU Y, Lu R, Su L, Lan K, et al
    Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    HIV Med. 2024 Mar 17. doi: 10.1111/hiv.13632.
    PubMed     Abstract available


  343. VIOLETTE LR, Thomas KK, Dorward J, Quame-Amaglo J, et al
    Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa.
    HIV Med. 2024 Mar 15. doi: 10.1111/hiv.13633.
    PubMed     Abstract available


  344. ZHAO J, Zhang L, Li L, Xie X, et al
    Growth of infants delivered by mothers with HIV in Guangxi, China: An 18-month longitudinal follow-up study, 2015-2021.
    HIV Med. 2024 Mar 13. doi: 10.1111/hiv.13624.
    PubMed     Abstract available


  345. TAHA AM, Elrosasy A, Mahmoud AM, Saed SAA, et al
    The effect of HIV and mpox co-infection on clinical outcomes: Systematic review and meta-analysis.
    HIV Med. 2024 Mar 5. doi: 10.1111/hiv.13622.
    PubMed     Abstract available


  346. PALICH R, Rodger AJ, Nicholls EJ, Wright T, et al
    Experiences with health care services and HIV testing after sexual assault in cisgender gay, bisexual and other men who have sex with men and transgender people.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13629.
    PubMed     Abstract available


  347. FURSA O, Bannister W, Neesgaard B, Podlekareva D, et al
    SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13620.
    PubMed     Abstract available


  348. NOE S, Ivanova A, Johnsson-Oldenbuttel C, Schafer G, et al
    Immunological alterations with GLP-1 agonists in people living with HIV.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13631.
    PubMed    


    September 2023
  349. LUI GC, Wong GL, Yang HC, Sheng WH, et al
    Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia.
    HIV Med. 2023 Sep 21. doi: 10.1111/hiv.13545.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum